Overview

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Study of the combination of acalabrutinib (ACP-196) and pembrolizumab in subjects with advanced head and neck squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Acerta Pharma BV
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Acalabrutinib
Pembrolizumab